HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Hsia, C. C.W. Articles by Raskin, P. PubMed PubMed Citation Articles by Hsia, C. C.W. Articles by Raskin, P. Related Collections Related Article Social Bookmarking                What's this?

Lung Involvement in Diabetes

Does it matter?

From the Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas

Address correspondence and reprint requests to Connie C.W. Hsia, MD, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9034. E-mail: connie.hsia@utsouthwestern.edu

Abbreviations: DL_CO, lung diffusing capacity • FEV₁, forced expiratory flow in 1 s • FVC, forced vital capacity

The first 20% of the full text of this article appears below.

Dyspnea upon exertion in a diabetic patient readily arouses suspicion of cardiovascular disease and/or physical deconditioning. As reviewed in our previous publications (1), a solid body of literature in the 1980s and 1990s established the occurrence of ventilatory restriction in type 1 diabetes; however, diabetic lung involvement did not gain wide recognition among internists until two recent developments helped change that perception. The first development is the cumulative data that demonstrate a pattern of modest lung restriction in type 2 diabetes qualitatively similar to that in type 1 diabetes, with proportional decreases in forced vital capacity (FVC) and forced expiratory flow in 1 s (FEV₁) that are directly related to glycemia (2–5) and a corresponding reduction in lung diffusing capacity (DL_CO) (6,7), the primary noninvasive measure of alveolar gas exchange capacity. As the prevalence of type 2 diabetes approaches epidemic proportions and pulmonary function emerges as an independent predictor of incident diabetes (8), pathophysiology of lung involvement also assumes greater relevance. The second development was the finding that chronic use of inhaled insulin could potentially trigger or exacerbate pulmonary dysfunction. Though shown to be efficacious and well tolerated, inhaled insulin has also been reported to cause a small early drop in spirometry and DL_CO at rest that did not progress during 2 years of follow-up (9). Its effects over longer duration of use and in the presence of primary lung disease, inflammation, or tobacco exposure are not clear. As inhaled insulin products continue to be developed, the spectacular collapse of Exubera notwithstanding, . . . [Full Text of this Article]

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article:

Cross-Sectional and Prospective Study of Lung Function in Adults With Type 2 Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study

Hsin-Chieh Yeh, Naresh M. Punjabi, Nae-Yuh Wang, James S. Pankow, Bruce B. Duncan, Christopher E. Cox, Elizabeth Selvin, and Frederick L. Brancati
Diabetes Care 2008 31: 741-746. [Abstract] [Full Text] [PDF]